Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody-based tumour diagnostics - Enlyton

Next Previous
Drug Profile

Research programme: antibody-based tumour diagnostics - Enlyton

Alternative Names: ENL-210

Latest Information Update: 02 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enlyton
  • Developer Enlyton; InfinixBio; Ohio State University; Quanta BioDesign
  • Class Antibody diagnostics; Imaging agents; Monoclonal antibodies; Radiopharmaceutical diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Adenocarcinoma

Most Recent Events

  • 02 Jan 2023 Discontinued - Preclinical for Adenocarcinoma (Diagnosis) in USA (Parenteral)
  • 28 Jan 2020 No recent reports of development identified for preclinical development in Adenocarcinoma(Diagnosis) in USA (Parenteral)
  • 07 Feb 2019 Applied Biomolecular Technologies has merged with Molecular Technologies Laboratories to form InfinixBio
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top